Akari Therapeutics, Plc
AKTX
$3.06
-$2.09-40.58%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 9.28M | 10.19M | 9.92M | 9.71M | 10.71M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.10M | 13.16M | 12.79M | 15.23M | 17.69M |
| Operating Income | -12.10M | -13.16M | -12.79M | -15.23M | -17.69M |
| Income Before Tax | -18.30M | -16.86M | -12.27M | -17.93M | -19.79M |
| Income Tax Expenses | -1.00M | -1.09M | -- | -- | -- |
| Earnings from Continuing Operations | -17.30 | -15.77 | -12.27 | -17.93 | -19.79 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -17.30M | -15.77M | -12.27M | -17.93M | -19.79M |
| EBIT | -12.10M | -13.16M | -12.79M | -15.23M | -17.69M |
| EBITDA | -12.08M | -13.15M | -12.78M | -15.22M | -17.68M |
| EPS Basic | -1.65M | -1.88M | -2.01M | -4.38M | -6.60M |
| Normalized Basic EPS | -8.67 | -10.51 | -13.22 | -25.80 | -43.05 |
| EPS Diluted | -1.65M | -1.88M | -2.01M | -4.38M | -6.60M |
| Normalized Diluted EPS | -8.67 | -10.51 | -13.22 | -25.80 | -43.05 |
| Average Basic Shares Outstanding | 3.37M | 2.77M | 2.26M | 1.71M | 1.19M |
| Average Diluted Shares Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |